Infectious Disease - Resistant Enterobacteriaceae (Diagnosis)
Conditions
Brief summary
The aim of this study was to compare the frequency of occurrence of digestive carrying of 3rd generation cephalosporin-resistant enterobacteriaceae (EB C3G-R), acquired during hospitalization in one of the participating departments, between patients treated with ceftriaxone and patients treated with cefotaxime
Interventions
DRUGCefotaxime Injection
Systematic use of cefotaxime.
PROCEDURERectal swab
Rectal swab every 3 days during hospitalization and then 30 days after the first antibiotic infusion
DRUGCefotaxime/ceftriaxone
ceftriaxone or cefotaxime infusion at the discretion of the prescribing physician
Sponsors
Centre Hospitalier Universitaire de Besancon
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
stepped-wedge design
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years old * Indication for antibiotic treatment with a 3rd generation injectable cephalosporin (cefotaxime or ceftriaxone) * Signed Informed Consent
Exclusion criteria
* Hypersensitivity to ceftriaxone or cefotaxime, to another cephalosporin or to any of the excipients of the specialities concerned. * History of severe hypersensitivity (e.g., anaphylactic reaction) to another class of antibacterial agent of the beta-lactam family (penicillins, monobactams and carbapenes) * Subcutaneous administration of ceftriaxone * Pregnant and breastfeeding woman * Suspicion of Pseudomonas infection or documented Pseudomonas infection requiring ceftazidime treatment * Suspicion of group III enterobacteriaceae infection or group III enterobacteriaceae infection requiring cefepime treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of occurrence of digestive carrying of EB C3G-R | 30 days after inclusion | Frequency of occurrence of digestive carrying of EB C3G-R |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| incidence rate of EB C3G-R infections | 2 years | Evaluate the effect of systematic use of cefotaxime rather than ceftriaxone on the incidence rate of EB C3G-R infections in participating departments. |
| number of patients with occurrence of positive rectal swab with 3rd generation cephalosporin-resistant enterobacteriaceae (EB C3G-R) | 30 days after inclusion | Compare the number of patients with occurrence of positive rectal swab with 3rd generation cephalosporin-resistant enterobacteriaceae (EB C3G-R), 30 days after inclusion, between patients treated with ceftriaxone and patients treated with cefotaxime. |
Countries
France
Outcome results
None listed